Page 115 - Read Online

Page 10 of 12 Procaccianti et al. Microbiome Res Rep 2023;2:24 https://dx.doi.org/10.20517/mrr.2023.23

negative and gram-positive bacteria. Molecules 2019;24:3770. DOI PubMed PMC
25. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature
2011;469:543-7. DOI
26. Yao S, Zhao Z, Wang W, Liu X. Bifidobacterium longum: protection against inflammatory bowel disease. J Immunol Res
2021;2021:8030297. DOI PubMed PMC
27. Wieërs G, Verbelen V, Van Den Driessche M, et al. Do probiotics during in-hospital antibiotic treatment prevent colonization of gut
microbiota with multi-drug-resistant bacteria? Front Public Health 2020;8:578089. DOI PubMed PMC
28. Hevia A, Milani C, López P, et al. Allergic patients with long-term asthma display low levels of bifidobacterium adolescentis. PLoS
One 2016;11:e0147809. DOI PubMed PMC
29. Gao X, Jia R, Xie L, Kuang L, Feng L, Wan C. Obesity in school-aged children and its correlation with gut e.coli and bifidobacteria: a
case-control study. BMC Pediatr 2015;15:64. DOI PubMed PMC
30. Taverniti V, Guglielmetti S. Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World J
Gastroenterol 2014;20:8821-36. DOI PubMed PMC
31. Murri M, Leiva I, Gomez-Zumaquero JM, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a
case-control study. BMC Med 2013;11:46. DOI PubMed PMC
32. Groeger D, O'Mahony L, Murphy EF, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.
Gut Microbes 2013;4:325-39. DOI PubMed PMC
33. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-
173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther
2009;29:104-14. DOI PubMed
34. Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of bifidobacterium lactis and
streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005;39:385-9. DOI
PubMed
35. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the
incidence of c. difficile diarrhoea. Int Microbiol 2004;7:59-62. PubMed
36. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a
multicenter, randomized, controlled trial. Pediatrics 2008;122:693-700. DOI
37. Singh A, Hacini-Rachinel F, Gosoniu ML, et al. Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in
individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial. Eur J
Clin Nutr 2013;67:161-7. DOI
38. López P, de Paz B, Rodríguez-Carrio J, et al. Th17 responses and natural IgM antibodies are related to gut microbiota composition in
systemic lupus erythematosus patients. Sci Rep 2016;6:24072. DOI PubMed PMC
39. Yeşilova Y, Çalka Ö, Akdeniz N, Berktaş M. Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol
2012;24:189-93. DOI PubMed PMC
40. D’Amico F, Barone M, Tavella T, Rampelli S, Brigidi P, Turroni S. Host microbiomes in tumor precision medicine: how far are we?
Curr Med Chem 2022;29:3202-30. DOI PubMed
41. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 2017;17:271-85. DOI PubMed
42. Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res
2011;71:661-5. DOI
43. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science
2013;342:971-6. DOI PubMed PMC
44. Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced
therapeutic immunomodulatory effects. Immunity 2016;45:931-43. DOI PubMed
45. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Science 2018;359:97-103. DOI PubMed PMC
46. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Science 2018;359:104-8. DOI PubMed PMC
47. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Science 2018;359:91-7. DOI PubMed
48. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science
2015;350:1079-84. DOI PubMed PMC
49. Motzer RJ, Escudier B, McDermott DF, et al; Checkmate 025 investigators. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803-13. DOI PubMed PMC
50. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J
Med 2015;373:1627-39. DOI PubMed PMC
51. Carbone DP, Reck M, Paz-Ares L, et al; CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell
Lung Cancer. N Engl J Med 2017;376:2415-26. DOI PubMed PMC
52. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20. DOI
53. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61. DOI PubMed